ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CYNA Cynapsus Therapeutics Inc. (MM)

40.4805
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cynapsus Therapeutics Inc. (MM) NASDAQ:CYNA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 40.4805 20.12 40.54 0 01:00:00

Termination of Registration of a Class of Security Under Section 12(b) (15-12b)

01/11/2016 5:25pm

Edgar (US Regulatory)


 

  OMB APPROVAL
  OMB Number: 3235-0167
  Expires: March 31, 2018
  Estimated average burden
  hours per response 1.50

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

 

001-37426

Commission File Number

 

SUNOVION CNS DEVELOPMENT CANADA ULC

 (Exact name of registrant as specified in its charter)

 

828 Richmond Street West, Toronto, Ontario, Canada M6J 1C9, (416) 703-2449

 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Shares, no par value

 (Title of each class of securities covered by this Form)

 

Not Applicable

 (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1) x  
Rule 12g-4(a)(2) ¨  
Rule 12h-3(b)(1)(i) x  
Rule 12h-3(b)(1)(ii) ¨  
Rule 15d-6 ¨  
Rule 15d-22(b) ¨  

  

Approximate number of holders of record as of the certification or notice date: One

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Dated: November 1, 2016

 

  Sunovion CNS Development Canada ULC
   
  By: /s/ Gregory Bokar
  Name: Gregory Bokar
  Title:   Director

 

 

1 Year Cynapsus Therapeutics Inc. Chart

1 Year Cynapsus Therapeutics Inc. Chart

1 Month Cynapsus Therapeutics Inc. Chart

1 Month Cynapsus Therapeutics Inc. Chart

Your Recent History

Delayed Upgrade Clock